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How can we predict bacterial eradication? 
Michael R. Jacobs@) 
Antimicrobial efficacy is measured in vitro by determination of minimum inhibitory concentrations (MICs) and 
minimum bactericidal concentrations (MBCs) of antimicrobials, but these values do not account for fluctuations of 
drug concentrations within the body or the time course of the drug’s in vivo antibacterial activity. However, in vivo 
bacteriologic efficacy can be predicted by pharmacokinetic/pharmacodynamic (PKPD) parameters, such as the time 
for which the serum drug concentration is above the MIC (T >MIC), the ratio of peak serum concentration to the 
MIC, and the ratio of the area under the 24-h serum concentration-time curve to the MIC (AUC/MIC). Different 
patterns of antibacterial activity correlate with different PK/PD parameters. For example, a T >MIC of 40-50% of 
the dosing interval is a good predictor of bacteriologic efficacy for penicillins, cephalosporins, and most macrolides, 
and an AUCYMIC ratio of at least 25 is required for efficacy with fluoroquinolones and azalides. The PK/PD 
breakpoint for susceptibility of an organism to a specific dosing regimen of an agent can be determined as the highest 
MIC met by the relevant PK/PD parameter for bacteriologic efficacy for that agent. These parameters have been 
validated extensively in animal models, as well as in many human studies where bacteriologic outcome has been 
determined. The PK/PD breakpoint of an agent is determined primarily by the dosing regimen, and generally applies 
to all pathogens causing disease at sites where extracellular tissue levels are similar to non-protein-bound serum 
levels. On this basis, many parenteral p-lactams are active against almost all strains of Streptococcus pneumoniae, 
including ‘penicillin-non-susceptible’ strains, in all body sites except for the central nervous system. Application of 
PK/PD breakpoints to standard dosing regimens of oral P-lactams predicts that agents such as cefaclor and cefixime 
will have efficacy only against penicillin-susceptible strains of S. pneumoniae, while cefuroxime axetil, cefpodoxime 
and cefdinir will be effective against all penicillin-susceptible as well as many penicillin-intermediate strains. 
However, the most active oral p-lactams, amoxicillin and amoxicillin-clavulanate, have predicted efficacy against 
all penicillin-susceptible and -intermediate pneumococci, as well as against most penicillin-resistant strains, at 
amoxicillin doses of 45-90 mg/kg per day in children and 1.75-4.0 g/day in adults. These predictions are supported 
by evidence from animal studies of bacteriologic efficacy. The use of PK/PD parameters to predict bacterial 
eradication therefore allows an evidence-based approach to the selection of appropriate antimicrobial therapy. 
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INTRODUCTION 
The introduction of antimicrobial agents, more than 50 
years ago, considerably reduced morbidity and mortality 
among patients with respiratory tract infections (RTIs). 
However, the problem of antimicrobial resistance 
among the major respiratory pathogens (Streptococcus 
pneumoniae, Haemophilus influenzae, and Moraxella 
catarrhalis) has been increasing rapidly in many regions, 
with the potential to reduce the efficacy of some oral 
antimicrobials. Consequently, there is an ongoing need 
to re-evaluate therapeutic choices in RTIs, to ensure that 
the primary goal of antimicrobial therapy-maximum 
bacterial killing-is met. This paper considers the 
various issues relating to optimal bacterial eradication in 
RTIs, including: accurate prediction of bacteriologic 
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efficacy, optimized dosing regimens, novel antimicrobial 
formulations, and pharmacokinetic (PK)/pharmaco- 
dynamic (PD)-based susceptibility breakpoints. 
EVALUATING ANTIMICROBIAL EFFICACY 
PK and PD characteristics both influence antimicrobial 
efficacy. Traditional predictions of antimicrobial efficacy 
have focused on in vitro activity (i.e. MIC) and 
pharmacokinetics, particularly the serum concentration 
profile of a drug over time, as well as its penetration into 
the site of infection. Recently, PD parameters-i.e. those 
describing the relationship between serum concentra- 
tions and drug pharmacology and toxicology-have 
assumed greater importance. Today, the integration of 
PK and PD characteristics (i.e. the PK/PD relationship 
for a drug) is central to our understanding of drug dose 
and efficacy. 
The specific PK/PD parameter correlating with 
bacteriologic efficacy is mostly dependent on whether 
bacterial killing is concentration- or time-dependent 
(Table l).l For time-dependent agents, such as p-lactams 
and macrolides, it is important that the dosing regimen 
maximizes the duration of time above the MIC (T >MIC) 
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Table 1. PWPD parameters predictive of antimicrobial efficacy based on unbound plasma levels. Adapted with permission l 
Antimicrobial effect 
Time-dependent killing 
and minimal/moderate 
persistent effects 
Time-dependent killing 
and prolonged 
persistent effects 
Concentration-dependent 
killing and prolonged 
persistent effects 
PKIPD parameter 
Proportion of dosing interval 
for which unbound serum 
drug level is above MIC 
(T>MIC) 
PKIPD target 
Unbound serum concentration 
present for approximately 
40% of the dosing interval 
Antimicrobial class 
Carbapenems 
Cephalosporins 
Clindamycin 
Macrolides 
Monobactams 
Oxazolidinones 
Penicillins 
Unbound 24-h serum 
AUC/MIC ratio 
Unbound 24-h serum 
AUUMIC ratio or 
peak/MIC ratio 
Unbound serum 24-h AUUMIC ratio 
225-30 (immunocompetent) or 
>I00 (immunocompromised) 
Unbound serum 24-h AUCIMIC 
ratio >25-30 or peak/MIC 23 
(immunocompetent) or 
Unbound serum 24-h AUClMlC 
ratio >I00 or peak/MIC >I2 
(immunocompromised) 
Streptogramins 
Tetracyclines 
Vancomycin 
Fluoroquinolones 
Azalides 
Aminoglycosides 
Ketolides 
MIC, minimum inhibitory concentration; AUC, area under serum drug concentration-time curve. 
of the agent against the target pathogen2 The unbound 
drug serum concentration present for >40-50% of the 
dosing interval is predictive of bacteriologic efficacy 
(bacterial eradication), and can be used to determine a 
PK/PD breakpoint for that specific dosing regimen.3 It 
has been argued that, for macrolides, tissue rather than 
serum concentrations determine efficacy; however, the 
major RTI pathogens are located in the extracellular 
rather than the intracellular compartment. Thus, the 
high intracellular concentrations of macrolides may 
actually decrease their therapeutic potential in these 
infections.4 Successful bacteriologic efficacy predictions 
for p-lactams and for macrolides, such as erythromycin 
and clarithromycin, are based on unbound serum con- 
centrations present for 40-50% of the dosing interval. 
For agents with concentration-dependent killing, 
such as fluoroquinolones and azalides (e.g. azithromycin), 
the 24-h unbound serum AUC/MIC ratio and the peak 
unbound serum concentration/MIC ratio both correlate 
with outcome.1,2 For concentration-dependent killing, the 
unbound serum 24-h AUC/MIC ratio needs to be 2 25 for 
less severe infections or in immunocompetent hosts, and 
2 100 in severe infections or in the immunocompromised 
patient.3 For concentration-dependent agents, therefore, 
the PK/PD breakpoint can be calculated using the follow- 
ing formula: unbound serum AUc~25.~ Consequently, if 
a penicillin (time-dependent killing) and a fluoro- 
quinolone (concentration-dependent killing) had com- 
parable in vitro activity against a specific pathogen and 
comparable PK, the PD characteristics determining their 
dosing regimen would be quite different.l 
BACTERIAL ERADICATION IN HUMANS- 
HOW PREDICTIVE ARE ANIMAL MODELS? 
Many studies indicate that the magnitude of the PK/PD 
parameter required for antimicrobial efficacy is similar 
in various animal species and in humans.5,6 Conse- 
quently, data from experimental models of infection can 
predict antimicrobial activity in humans. This is parti- 
cularly valuable during drug development and when 
there are difficulties in collecting sufficient data to 
demonstrate definitive bacteriologic efficacy in humans 
(e.g. in clinical syndromes where spontaneous recovery 
is high, such as otitis media and sinusitis, or when 
bacteriologic sampling is problematic, such as in patients 
with pneumonia).3 
Time-dependent killing 
Craig reported on the relationship between T >MIC 
and bacterial eradication in animal models infected with 
S. pneumoniae, in which mortality was used as the 
endpoint.5T7 The infected animals were treated for 
several days with either a penicillin or a cephalosporin. 
The mortality rate was almost 100% if unbound serum 
levels were above the MIC for ~20% of the dosing 
interval; however, once the T >MIC exceeded 40-50%, 
survival was 90-100% (Figure 1). Clinical support for 
this principle has been obtained from numerous studies 
of sinusitis and otitis media.8 Using data collected 
from patients with these infections, the investigators 
calculated the T >MIC for each of the dosing regimens 
from mean serum concentrations and MICs for different 
pathogens (Figure 2). High rates of bacteriologic cure 
(>80%) were achieved once the T >MIC exceeded 
40% of the dosing interval. The relationship between 
T >MIC and bacterial eradication was investigated 
by Berry et al in a rat model of experimental pneumo- 
coccal pneumonia.9 Pneumococcus is a difficult pathogen 
to work with in rodents, as it is not naturally virulent 
in these animals. In order to establish infection, it is 
necessary to introduce agar beads containing lo6 CFU 
,S. pneumoniae intrabronchially into each animal. Dosing 
is then initiated to simulate the human serum pharma- 
cokinetics obtained with different dosing regimens. 
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Figure 1. Relationship between the length of time for which 
serum levels of p-lactams exceed the MIC (T>MIC) and survival 
in animal models infected with 5. pneumoniae. Reproduced 
with permission.7 
Antimicrobial treatment begins 24 h after infection 
and is continued for 3 days, after which the animals are 
killed and the lungs removed for the enumeration of 
viable bacteria. Berry et al simulated the human PK 
profiles of different oral amoxicillin-clavulanate 
formulations (500/125 mg t.i.d., 875/125 mg b.i.d. and 
t.i.d., 10001125 mg t.i.d., and the new pharmaco- 
kinetically enhanced formulation, 2000/125 mg b.i.d.) 
by intravenous infusion of doses calculated using 
a linear one-compartment absorption model.9 The 
new pharmacokinetically enhanced 2000/125 mg b.i.d. 
100 
0 
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Figure 2. Relationship between T >MICgo and bacteriologic 
cure for 5. pneumoniae and H. influenzae in the treatment of 
otitis media and acute maxillary sinusitis. Reproduced with 
permission.8 PSSP, penicillin-susceptible 5. pneumoniae; PISP, 
penicillin-intermediate 5. pneumoniae; PRSP, penicillin-resistant 
5. pneumoniae. 
formulation of amoxicillin-clavulanate achieved sig- 
nificant reductions in bacterial load against three 
S. pneumoniae strains with amoxicillin MICs of 4 mg/L 
and three with MICs of 8 mg/L. The efficacy of 
amoxicillin-clavulanate 2000/125 mg b.i.d. was superior 
to that of the other formulations against all three 
S. pneumoniae strains with amoxicillin MICs of 8 mg/L. 
This is consistent with predictions based on T >MIC.9 
Other formulations were effective against strains of 
S. pneumoniae with amoxicillin MICs of 2-4 mg/L 
(Figure 3). 
(a) 875/125 mg b.i.d. or (b) 2000/125 b.i.d. 
500/125 mg t.i.d. 
90 mg/kg/day (4 mg 
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Figure 3. Efficacy of amoxicillin-clavulanate against 5. pneumoniae in an animal model of respiratory tract infection at various 
dosing regimens9 There was a ~3 loglo reduction in bacterial load: (a) when the amoxicillin MIC was 2 but not 4 mg/L at dosing 
regimens equivalent to 875/125 mg b.i.d. or 500/125 mg t.i.d. formulations; (b) when amoxicillin MlCs were 2 and 4 mg/L at dosing 
regimens equivalent to the 90/6.4 mg/kg per day formulation; and (c) when amoxicillin MlCs were 2, 4 and 8 mg/L at dosing 
regimens equivalent to the pharmacokinetically enhanced 2000/125 mg b.i.d. formulation.9,17,18 
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Concentration-dependent killing 
Berry et al also used the rat model of pneumococcal 
pneumonia to evaluate the predictive value of the 
AUCYMIC ratio for various fluoroquinolones.lO*ll 
A 22 loglo drop in bacterial load is associated with a 
significant difference compared with controls in this 
model. Between five and nine animals were infected for 
each experiment, plus saline-treated controls. When the 
AUCYMIC ratio was ~5, there was generally a less than 
2 log10 kill, i.e. little bacterial eradication. When the 
AUC/MIC ratio exceeded 25, however, bacterial killing 
of >2 log10 was reliably achieved (Figure 4). However, 
it is of note that the bactericidal activity of the fluoro- 
quinolones in this model is 1 loglo (i.e. 10 times) less than 
that of p-lactam antimicrobials.lOJ1 
Support for these data in the clinical setting was 
provided by a PK/PD study performed by Preston et 
a1.12 These investigators prospectively quantified the 
relationship between plasma levels of levofloxacin and 
clinical outcome. The study included 134 hospitalized 
patients with a pathogen recovered from the primary 
site of infection for which the levofloxacin MIC had 
been determined. Patients had RTIs, skin infections, or 
complicated urinary tract infections (UTIs), and were 
treated with levofloxacin 500 mg, intravenously, o.d., for 
5-14 days. Results showed that when the AUCYMIC 
ratio was ~25 (or peak/MIC ratio was <3), the clinical 
failure rate was 43% (3/7 patients). However, when the 
AUC/MIC ratio was between 25 and 100 (or peak/MIC 
ratio was 3-12), the clinical failure rate was just 11.5% 
(3/26 patients); and when the AUC/MIC ratio exceeded 
100 (or the peak/MIC ratio was > 12) the clinical failure 
rate was virtually zero (l/101 patients) (Figure 5). In the 
case of levofloxacin, the AUC/MIC ratio of 25 or higher 
based on unbound plasma levels required for in vivo 
efficacy is equivalent to an AUC/MIC ratio of 40 or 
n ~2 log kill q >2 log kill 
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AUClMlC 6 AUCYMIC 5-25 AUC/MIC 225 
Unbound serum AUClMlC ratio 
>2 log kill 0% 42% 100% 
p>O.OOl for AUClMlC ratio c5 versus >5, and ~25 versus >25 (Fisher exact test) 
Figure 4. Fluoroquinolone unbound AUUMIC ratio and 
bacterial killing in the rat 5. pneumoniae pneumonia model. 
Only when the AUUMIC ratio exceeds 25 is reliable bacterial 
eradication achieved.‘O,ll 
higher based on total plasma levels, as about one-third 
of this agent is protein bound. Overall, these data validate 
many of the factors that have been seen in animal 
models, and indicate that the levofloxacin PK/PD para- 
meters described in animals are relevant in humans. 
DOSING REGIMENS, PK/PD BREAKPOINTS, 
AND ANTIMICROBIAL EFFICACY 
As PK/PD parameters can predict antimicrobial 
efficacy, an antimicrobial agent can be considered likely 
to be useful in the empirical treatment of RTIs if the 
MI& of the agent against S. pneumoniae, H. influenzae, 
and 44. catarrhalis is at or below its PK/PD breakpoint. 
Given the ongoing increase in microbial drug resistance, 
there is an increasing need for clinicians to question 
whether dosing regimens of commonly used agents 
achieve sufficiently high serum PD parameters for 
bacterial eradication. Table 2 provides an overview of 
common dosing regimens for cefaclor, cefuroxime axetil, 
amoxicillin-clavulanate, clarithromycin, and azithro- 
mycin, their MICROS against the key RTI pathogens, 
and the PK/PD breakpoints associated with their dosing 
regimens.i3-Is 
For cefaclor, cefuroxime axetil, amoxicillin-clavu- 
lanate, and clarithromycin, PK/PD breakpoints reflect 
the serum concentrations present for 40% of the dosing 
interval based on approved dosing regimens. For 
azithromycin, the PK/PD breakpoint represents the 
24-h serum AUCe-25 (see previous section). For 
example, the most commonly used oral regimen of 
amoxicillin-clavulanate in adults is 875/125 mg b.i.d. The 
serum amoxicillin concentration that is present for 
n Success 0 Failure 
AUClMlC ~25 AUClMlC 25-100 AUC/MIC >I00 
PeaklMIC ~3 Peak/MIC 3-12 Peak/MlC >I2 
Clinical 
failure rate 43% 11.5% 
Figure 5. Correlation between levofloxacin PWPD and clinical 
outcome in 134 hospitalized patients with respiratory tract, 
skin or complicated urinary tract infections treated with 
levofloxacin 500 mg once daily for 5-14 days. Adapted with 
permission.12 
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Table 2. PWPD breakpoints of commonly used antimicrobial agents and MI& values for common RTI pathogens13-‘* 
Drug 
P-Lactams 
Cefaclor 
Dosing regimen 
(pediatric; adult) 
20-40 mglkglday (2 or 3 
divided doses); 
250-500 mg (t.i.d.) or 
500 mg extended release (b.i.d.) 
Streptococcus Haemophilus Moraxella PKIPD 
pneumoniae influenzae catarrhalis breakpoint 
(M&o mglL) (MlC90 mglL) fMIC90 mglL) (mglL) 
Pen-S Pen-l Pen-R 
2 64 264 16 16 so.5 
Cefuroxime axetil 30 mglkglday (2 divided doses); 0.12 4 8 2 2 51 
500 (b.i.d.) mg 
AMWCAa 45/6.4 mglkglday (2 divided doses); 0.03 1 4 1 0.25 52 
875/125 (b.i.d.) mg 
AMXICAa 90/6.4 mglkglday (2 divided doses); 0.03 1 4 1 0.25 54 
PK enhanced 20001125 mg (b.i.d.) 
Macrolides 
Clarithromycin 
AzithromycinC 
Susceptible mefEb ermBb 
15 mglkglday (2 divided doses); 0.06 4 232 
250-500 (b.i.d.) mg 
10 mg day 1 followed by 5 mg/kg 
days 2-5; 500 mg day 1 followed 0.06 4 232 
by 250 mg days 2-5 
16 0.12 50.25 
16 0.03 SO.12 
Pen-S, penicillin susceptible; Pen-l, penicillin intermediate; Pen-R, penicillin resistant; AMWCA, amoxicillin-clavulanate. 
a Dosing based on amoxicillin component. 
b Macrolide-resistant strains of 5. pneumoniae. 
L For azithromycin, the key PWPD parameter is AUUMIC. PWPD breakpoint calculated as AUCt25. 
240% of the dosing interval is 2 mg/L. This con- 
centration represents the amoxicillin-clavulanate 
875/125 mg b.i.d. PKiPD breakpoint, and predicts that 
this dosing regimen of amoxicillin-clavulanate will be 
effective against pathogens with amoxicillin-clavulanate 
MICs of up to 2 mg/L. Thus, amoxicillin-clavulanate 
875/125 mg is likely to be effective against all of the key 
RTI pathogens, except for the most highly penicillin- 
resistant strains of S. pneumoniae (Table 2).i3-15 
Of the p-lactams shown in Table 2, cefaclor is 
the least active and is unlikely to be very effective in 
bacterial RTIs. Cefuroxime axetil is significantly more 
active, and likely to be effective against all penicillin- 
susceptible S. pneumoniae strains and some penicillin- 
intermediate S. pneumoniae, H. influenzae, and M. catarr- 
halis strains, but not penicillin-resistant S. pneumoniae. 
Amoxicillin-clavulanate remains the most active of the 
p-lactam agents, and, in fact, is the only oral l3-lactam to 
exceed the MIGos of all three pathogens for 240% of 
the dosing interval (Table 3).3 As highlighted above, the 
most common dosing regimen (8751125 mg b.i.d. in 
adults, or its equivalent, 4516.4 mglkg per day in two 
divided doses in children) is associated with an 
amoxicillin-clavulanate breakpoint of 2 mg/L, and 
covers most RTI pathogens, including 70-80% of 
penicillin-resistant S. pneumoniae strains. Although the 
prevalence of strains resistant to amoxicillin and 
amoxicillin-clavulanate is generally low, there are some 
locations where penicillin-resistant S. pneumoniae 
strains are emerging that are associated with MICs for 
amoxicillin or amoxicillin-clavulanate of 22 mg/L. To 
maintain the bacteriologic efficacy of amoxicillin-clavu- 
lanate, two new formulations of amoxicillin-clavulanate 
with improved PK/PD profiles have been developed. 
For pediatric use, a high-dose formulation has been 
developed (amoxicillin-clavulanate 90/6.4 mg/kg per 
day in two divided doses), with a PK/PD breakpoint of 
4 mg/L (Figure 6).This covers all the key RTI pathogens, 
including >95% of pneumococci (Table 4).17 An oral, 
high-dose, pharmacokinetically enhanced bilayer tablet 
has been developed for adults, comprising amoxicillin- 
clavulanate 2000/125 mg b.i.d. This new formulation 
consists of a layer of immediate-release amoxicillin and 
clavulanate and a layer of sustained-release amoxicillin 
in proportions such that, for an amoxicillin MIC of 
4 mg/L, the T >MIC is 49% of a 12-h dosing interval.ls 
This formulation also provides a serum concentration of 
8 mg/L for 35% of the dosing interval (Table 5; Figures 
3 and 6).9 
Table 2 indicates that, while both clarithromycin and 
azithromycin are likely to be bacteriologically effective 
against macrolide-susceptible strains of S. pneumoniae 
(MIC90 0.06 mg/L), they would be predicted to be 
bacteriologically ineffective against ermB- or mefE- 
mediated resistant strains. Consequently, these agents 
would be inappropriate for patients living in areas with 
high prevalences of macrolide resistance (Table 4).19 
Similarly, clarithromycin and azithromycin fail to 
achieve the serum PK parameters required for the 
eradication of H. influenzae.3~sJ3-16 
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Table 3. Percentage of dosing interval for oral p-lactams for which serum concentrations are above the MI&s of common 
respiratory tract infection pathogens3 
5. pneumoniae 
Dosing regimen Pen-S Pen-l Pen-R H. influenzae M. catarrhalis 
Cefaclor 500 t.i.d. mg 60 0 0 0 0 
Cefuroxime axetil 500 b.i.d. mg 75 35 0 33 33 
Amoxicillin-clavulanate 875/125 mg b.i.d. 100 59 46 41 70 
Pen-S, penicillin susceptible; Pen-l, penicillin intermediate; Pen-R, penicillin resistant. 
(4 90 mg/kg/day 
I 
0 12 24 
Time (h) 
2000/125 mg b.i.d. 
12 24 
Time (h) 
- - - Pen-R ME,, = 4 mg/L - PWPD BP = 4 mg/L 
* -  n Pen-l MIC,, = 1 mglL * - * H. influenzae ME,, = 1 mg/L 
‘- 11 Pen-S MIC,, = 0.03 mg/L ..... M. catarrhalis ME,, = 0.25 mg/L 
Figure 6. Use of PWPD breakpoints to predict antimicrobial 
activity for two high-dose amoxicillin-clavulanate formulations: 
(a) 90/6.4 mg/kg per day in two divided doses; and 
(b) pharmacokinetically enhanced amoxicillin-clavulanate 
2000/125 mg b.i.d. These dosing regimens lead to a breakpoint 
of 4 mg/L, and permit amoxicillin to be active against all 
common respiratory tract infection pathogens shown, including 
all penicillin-intermediate and most penicillin-resistant strains 
of 5. pneumoniae.‘7*‘8 
COMPARING PK/PD AND CURRENT NCCLS 
BREAKPOINTS 
Although the National Committee for Clinical Labora- 
tory Standards (NCCLS) is starting to take PK/PD 
parameters into consideration,20 there remains some 
degree of disagreement between NCCLS and PK/PD 
breakpoints. The main difference is that, for PK/PD 
assessment, each agent (in a particular dosing regimen) 
has only one breakpoint, and this is independent of the 
pathogen involved but specific for dose and even 
formulation, whereas NCCLS breakpoints vary accord- 
ing to the agent and the pathogen. The NCCLS has 
recognized the value of PKiPD breakpoints and the 
need to consider these to enable the use of optimal 
dosing regimens. NCCLS breakpoints for S. pneumoniae 
and p-lactams, issued in January 2000, reflect the import- 
ance of PK/PD relationships. However, there are still 
considerable discrepancies between PK/PD and NCCLS 
breakpoints for H. infEuenzae, particularly in the case of 
macrolides and some oral cephalosporins, and no 
NCCLS breakpoints exist for M. catarrhalis. 
In terms of antimicrobial selection for the empirical 
treatment of RTIs, PK/PD breakpoints are playing an 
increasingly important role. Geographic variation in 
susceptibility patterns is considerable, and Table 4 high- 
lights the susceptibilities of major RTI pathogens in 
regions worldwide to oral agents at PK/PD breakpoints.19 
Table 4 indicates that, against all three major pathogens, 
high-dose amoxicillin-clavulanate (90/6.4 mg/kg per 
day or pharmacokinetically enhanced 2000/125 mg b.i.d.) 
would cover 29.5% of S. pneumoniae, H. influenzae, and 
A4. catarrhalis strains (i.e. predictive bacterial eradica- 
tion).19 
CONCLUSIONS 
There is a great deal of evidence to suggest that PK/PD 
parameters can be used to predict bacterial eradication 
in both animal models and humans, and can be used to 
derive clinically relevant susceptibility breakpoints. 
For the p-lactam agent amoxicillin-clavulanate, optimal 
bacterial killing is achieved when the serum concen- 
tration remains above the MIC for approximately 
40% of the dosing interval. Oral dosing regimens of 
9016.4 mg/kg per day in two divided doses in children, 
and 20001125 mg b.i.d. of the sustained-release formul- 
ation in adults, produce serum concentrations of 
4 mg/L for at least 40% of the dosing interval. Con- 
sequently, pathogens with amoxicillin-clavulanate 
MICs of up to 4 mg/L are susceptible and likely to be 
eradicated. Additionally, the oral, adult formulation 
(2000/125 mg) is predicted to be potentially bacterio- 
logically effective against pathogens with MICs as high 
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Table 4. Susceptibility (%) of major respiratory tract infection pathogens at PWPD breakpoints: Alexander Project 2001’g 
Susceptibility (%) 
Agent 
PKIPD 
breakpoint 
@wlL) 
Worldwide USA Europe Far East 
SP HI MC SP HI MC SP HI MC SP HI MC 
AMWCA” 2 96.1 97.5 99.3 91.1 97.6 NA 97.5 99.7 100 98.4 88.0 94.7 
AMWCA high doseaeb 4 98.1 99.5 100 94.9 99.8 NA 98.6 100 100 100 96.3 100 
Amoxicillin 2 96.1 82.7 23.9 91.2 74.2 NA 97.5 87.6 26.0 97.9 74.1 10.5 
Cefaclor 0.5 15.2 2.3 8.4 15.5 5.5 NA 18.6 0.4 8.9 6.1 1.0 5.3 
Cefixime 1 66.5 99.5 100 67.9 99.8 NA 79.5 100 100 27.6 97.3 100 
Cefprozil 1 76.9 15.5 14.8 73.5 22.5 NA 85.1 12.8 16.3 52.0 9.0 5.3 
Cefuroxime 1 77.6 77.2 48.6 75.2 80.3 NA 85.1 79.5 47.2 53.6 62.1 57.9 
CeftriaxoneC NA 96.5 100 100 97.1 99.8 NA 97.2 100 100 93.4 77.7 100 
Erythromycin 0.25 69.8 0 0 71.7 0 NA 77.7 0 0 33.7 0 0 
Azithromycin 0.12 69.0 0.9 100 70.1 0.9 NA 77.1 0.7 100 33.7 2.3 100 
ClindamycitY NA 82.0 NA NA 90.9 NA NA 81.0 NA NA 69.0 NA NA 
Doxycycline 0.25 69.5 27.6 92.3 85.4 31.4 NA 76.7 27.4 91.9 24.9 15.9 94.7 
Levofloxacin 2 98.8 100 100 99.3 100 NA 99.5 100 100 94.7 100 100 
Cotrimoxazoled NA 66.0 76.8 98.6 64.4 77.7 NA 72.5 80.6 100 58.4 83.1 89.5 
SP, 5. pneumoniae; Hi, H. influenzae; MC, M. catarrhalis; AMXKA, amoxicillin-clavulanate; NA, no data available. 
a Susceptibility based on amoxicillin component. 
b PWPD breakpoint of 4 mg/L applies to the 90/6.4 mglkg per day pediatric formulation and the 20001125 mg b.i.d. adult 
formulation of amoxicillin-clavulanate. 
c Susceptibility based on NCCLS breakpoints: for ceftriaxone, 21 mg/L for 5. pneumoniae (non-meningitis), ~2 mg/L for H. influenzae 
(also used here for M. catarrhalis); for clindamycin, ~0.25 mg/L for 5. pneumoniae (H. influenzae and M. catarrhalis not tested). 
d Susceptibility based on trimethoprim component, NCCLS breakpoint ~0.5 mg/L. 
Table 5. T>MIC for pediatric and adult amoxicillin-clavulanate (AMXKA) formulations, The new, pharmacokinetically enhanced 
adult formulation (2000/125 mg) will provide coverage of pathogens with MlCs as high as 4 mg/L, while current formulations will 
provide coverage of pathogens with MlCs of 2-4 mg/L18,21 
AMXICA 
formulation 
Pediatric (mglkglday) 
4516.4 
40/l 0 
9016.4 
Adult (mg) 
500/l 2s 
87Sil25 
1000/l 25 
2000/l 25 
-, T >MIC of ~35%. 
Dosing regimen 
2 divided doses 
3 divided doses 
2 divided doses 
t.i.d. 
b.i.d. 
t.i.d. 
b.i.d. 
1 
50 
59 
61 
55 
44 
>65 
270 
T > MIC for amoxicillin 
% of dosing interval for MlCs (mg/L) of: 
2 4 8 
41 
44 
50 41 
43 
40 - 
55 41 - 
60 49 35 
as 8 mg/L. Clearly, amoxicillin-clavulanate remains a 
key antimicrobial agent for the treatment of RTIs in 
both children and adults. Its availability in several 
optimized formulations will help to reassure clinicians 
about its continued efficacy against drug-resistant 
pathogens in areas where these organisms constitute 
an emerging problem. 
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